JP2020091296A5 - - Google Patents

Download PDF

Info

Publication number
JP2020091296A5
JP2020091296A5 JP2020018129A JP2020018129A JP2020091296A5 JP 2020091296 A5 JP2020091296 A5 JP 2020091296A5 JP 2020018129 A JP2020018129 A JP 2020018129A JP 2020018129 A JP2020018129 A JP 2020018129A JP 2020091296 A5 JP2020091296 A5 JP 2020091296A5
Authority
JP
Japan
Prior art keywords
inflammatory agent
combination
pkal inhibitor
pkal
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020018129A
Other languages
English (en)
Japanese (ja)
Other versions
JP7157089B2 (ja
JP2020091296A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020091296A publication Critical patent/JP2020091296A/ja
Publication of JP2020091296A5 publication Critical patent/JP2020091296A5/ja
Priority to JP2022161469A priority Critical patent/JP7541560B2/ja
Application granted granted Critical
Publication of JP7157089B2 publication Critical patent/JP7157089B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020018129A 2013-10-21 2020-02-05 自己免疫疾患の診断と治療 Active JP7157089B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022161469A JP7541560B2 (ja) 2013-10-21 2022-10-06 自己免疫疾患の診断と治療

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361893542P 2013-10-21 2013-10-21
US61/893,542 2013-10-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016549205A Division JP6657098B2 (ja) 2013-10-21 2014-10-17 自己免疫疾患の診断と治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022161469A Division JP7541560B2 (ja) 2013-10-21 2022-10-06 自己免疫疾患の診断と治療

Publications (3)

Publication Number Publication Date
JP2020091296A JP2020091296A (ja) 2020-06-11
JP2020091296A5 true JP2020091296A5 (https=) 2020-11-12
JP7157089B2 JP7157089B2 (ja) 2022-10-19

Family

ID=52993412

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016549205A Active JP6657098B2 (ja) 2013-10-21 2014-10-17 自己免疫疾患の診断と治療
JP2020018129A Active JP7157089B2 (ja) 2013-10-21 2020-02-05 自己免疫疾患の診断と治療
JP2022161469A Active JP7541560B2 (ja) 2013-10-21 2022-10-06 自己免疫疾患の診断と治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016549205A Active JP6657098B2 (ja) 2013-10-21 2014-10-17 自己免疫疾患の診断と治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022161469A Active JP7541560B2 (ja) 2013-10-21 2022-10-06 自己免疫疾患の診断と治療

Country Status (14)

Country Link
US (3) US10101344B2 (https=)
EP (2) EP3060908B1 (https=)
JP (3) JP6657098B2 (https=)
KR (3) KR102295623B1 (https=)
CN (2) CN105874332B (https=)
AU (4) AU2014340449B2 (https=)
BR (1) BR112016008975B1 (https=)
CA (1) CA2927695C (https=)
DK (1) DK3060908T3 (https=)
ES (1) ES2873204T3 (https=)
IL (4) IL293948A (https=)
PL (1) PL3060908T3 (https=)
PT (1) PT3060908T (https=)
WO (1) WO2015061182A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234583A3 (en) * 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
CA2927695C (en) * 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
EP4354146B1 (en) 2015-10-19 2026-04-15 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
IL265195B2 (en) 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
KR200490846Y1 (ko) 2019-04-09 2020-01-13 이대호 각도조절 브라켓
US20230174674A1 (en) * 2020-04-04 2023-06-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
KR20230050770A (ko) 2021-10-08 2023-04-17 김경민 발로 열 수 있는 반려동물 울타리
EP4548103A2 (en) * 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
JPS63185398A (ja) 1986-09-10 1988-07-30 Nippon Zoki Pharmaceut Co Ltd 生理活性物質測定法
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993003748A1 (en) 1991-08-13 1993-03-04 Temple University - Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
WO1997014028A2 (en) 1995-10-11 1997-04-17 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
JP4106888B2 (ja) 2001-09-19 2008-06-25 カシオ計算機株式会社 液晶表示装置および携帯端末装置
US8148171B2 (en) 2001-10-09 2012-04-03 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7435542B2 (en) 2002-06-24 2008-10-14 Cornell Research Foundation, Inc. Exhaustive selection of RNA aptamers against complex targets
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
WO2004039487A1 (en) 2002-11-01 2004-05-13 Mcmaster University Multicomponent protein microarrays
WO2005024042A2 (en) 2003-09-04 2005-03-17 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
EP1700912B1 (en) 2003-11-22 2014-10-29 Techno Medica Co., Ltd. Method of detecting target molecule by using aptamer
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
PL1981519T3 (pl) 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
JP2010510528A (ja) * 2006-11-22 2010-04-02 ライフ テクノロジーズ コーポレーション 自己免疫疾患のバイオマーカー
US20080255766A1 (en) 2007-02-16 2008-10-16 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of sickle cell
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
AU2008315938B2 (en) 2007-10-22 2014-11-27 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
CA2729937A1 (en) * 2008-07-07 2010-01-14 Nippon Zoki Pharmaceutical Co., Ltd. Fibromyalgia test method
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
EP2369930A4 (en) 2008-12-02 2012-10-03 Joslin Diabetes Ct METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) * 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JP5299179B2 (ja) * 2009-09-02 2013-09-25 株式会社リコー 画像形成装置
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
AU2010330743A1 (en) 2009-12-18 2012-07-05 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9206123B2 (en) * 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
WO2012009447A2 (en) * 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
EP2645932B1 (en) 2010-12-02 2016-03-02 Becton, Dickinson and Company Blood collection devices containing blood stabilization agent
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
EP3320922A1 (en) 2011-06-10 2018-05-16 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
WO2012170947A2 (en) * 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
RU2015136025A (ru) 2013-02-01 2017-03-06 Бектон, Дикинсон энд Кампани Устройства для сбора крови, содержащие добавки, ингибирующие контактный путь свертывания крови
CA2927695C (en) 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
EP4354146B1 (en) 2015-10-19 2026-04-15 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
KR102874711B1 (ko) 2015-12-15 2025-10-23 다케다 파머수티컬 컴패니 리미티드 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
EP4096687A4 (en) * 2020-01-28 2024-02-28 Orgenesis Inc. Process and system for acellular therapy

Similar Documents

Publication Publication Date Title
JP2020091296A5 (https=)
Petito et al. Association of neutrophil activation, more than platelet activation, with thrombotic complications in coronavirus disease 2019
Le Joncour et al. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease
Ali et al. Lectin pathway mediates complement activation by SARS-CoV-2 proteins
Wang et al. Neutrophil extracellular trap-microparticle complexes enhance thrombin generation via the intrinsic pathway of coagulation in mice
Spaeny-Dekking et al. Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo
Chaaban et al. Inter-α inhibitor protein and its associated glycosaminoglycans protect against histone-induced injury
Muthas et al. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications
Bottomley et al. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid
Carbone et al. Pathophysiological role of neutrophils in acute myocardial infarction
Corsiero et al. NETosis as source of autoantigens in rheumatoid arthritis
Chang et al. The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis
Koenig-Oberhuber et al. New antiplatelet drugs and new oral anticoagulants
Langnau et al. Platelet activation and plasma levels of furin are associated with prognosis of patients with coronary artery disease and COVID-19
Jin et al. Neutrophil extracellular traps contribute to coagulopathy after traumatic brain injury
Hisada et al. Circulating tissue factor‐positive extracellular vesicles and their association with thrombosis in different diseases
Van Leuven et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease
Misra et al. Mechanisms of thrombosis in ANCA-associated vasculitis
Jin et al. Neutrophil extracellular traps promote thrombogenicity in cerebral venous sinus thrombosis
Boccatonda et al. Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection
Tomerak et al. Systemic inflammation in COVID‐19 patients may induce various types of venous and arterial thrombosis: a systematic review
Kwasny-Krochin et al. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis
Ercan et al. Platelet phenotype analysis of COVID-19 patients reveals progressive changes in the activation of integrin αIIbβ3, F13A1, the SARS-CoV-2 Target EIF4A1 and Annexin A5
Apetrii et al. A brand-new cardiorenal syndrome in the COVID-19 setting
Stephan et al. Activation of factor VII-activating protease in human inflammation: a sensor for cell death